Alumis, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2021-01-01
- Employees
- 11
- Market Cap
- $685.4M
- Website
- http://www.alumis.com
Clinical Trials
19
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (18 trials with phase data)• Click on a phase to view related trials
An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function
- First Posted Date
- 2025-05-08
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Alumis Inc
- Target Recruit Count
- 48
- Registration Number
- NCT06962774
- Locations
- 🇺🇸
Panax Clinical Research, Miami Lakes, Florida, United States
🇺🇸Floridian Clinical Research, Miami Lakes, Florida, United States
🇺🇸Advanced Pharma CR, Miami, Florida, United States
An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Alumis Inc
- Target Recruit Count
- 48
- Registration Number
- NCT06952634
- Locations
- 🇺🇸
Orange County Research Center, Lake Forest, California, United States
🇺🇸Panax Clinical Research, Miami Lakes, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
- Conditions
- Plaque PsoriasisPsoriasis (PsO)PsoriasisModerate PsoriasisSevere Psoriasis
- Interventions
- Drug: Open-Label ESK-001Drug: Blinded ESK-001Drug: Placebo
- First Posted Date
- 2025-02-26
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Alumis Inc
- Target Recruit Count
- 1680
- Registration Number
- NCT06846541
- Locations
- 🇺🇸
Total Dermatology, Birmingham, Alabama, United States
🇺🇸Chandler Clinical Trials, Chandler, Arizona, United States
🇺🇸Alliance Dermatology, Pheonix, Arizona, United States
A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001
- Conditions
- Plaque Psoriasis
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-06-20
- Lead Sponsor
- Alumis Inc
- Target Recruit Count
- 840
- Registration Number
- NCT06588738
- Locations
- 🇺🇸
Total Skin and Beauty Dermatology Center, PC, Birmingham, Alabama, United States
🇺🇸Chandler Clinical Trials, Chandler, Arizona, United States
🇺🇸Medical Dermatology Specialists, Phoenix, Arizona, United States
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis
- Conditions
- Plaque Psoriasis
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-06-20
- Lead Sponsor
- Alumis Inc
- Target Recruit Count
- 840
- Registration Number
- NCT06586112
- Locations
- 🇺🇸
Alliance Dermatology, Phoenix, Arizona, United States
🇺🇸Scottsdale Clinical Trials, Scottsdale, Arizona, United States
🇺🇸Northwest Arkansas Clinical Trials Center (NWACTC), PLLC, Rogers, Arkansas, United States
- Prev
- 1
- 2
- 3
- Next
News
Robust Pipeline of 80+ Therapies Advancing in Psoriasis Treatment Landscape
DelveInsight's 2025 Psoriasis Pipeline Report reveals over 80 companies developing 80+ pipeline therapies, highlighting significant R&D investment in this therapeutic area.
Alumis to Present 52-Week Phase 2 Data for Novel TYK2 Inhibitor in Psoriasis at AAD 2025
Alumis will showcase long-term safety and efficacy data for ESK-001, their oral TYK2 inhibitor, in moderate-to-severe plaque psoriasis through multiple presentations at the 2025 AAD annual meeting.